Explore
Rheumatoid Arthritis Therapy Reappraisal
0 Ungluers have
Faved this Work
Login to Fave
Rheumatoid Arthritis (RA) is a chronic inflammatory disease leading to joint inflammation and destruction. Treatment of RA includes the use of conventional (cs), biologic (b) disease-modifying anti-rheumatic drugs (DMARDs), and oral or intraarticular (IA) glucocorticoids (GCs). All different classes of drugs have shown to halt disease progression in clinical studies. In real life, a physician has more options than just adding or switching to a new ts/bDMARD if any kind of DMARDs has failed. They can modify or optimize the therapy with concomitant csDMARDs, and oral or IA-GC can be added to the treatment regimen. The EULAR states that therapeutic adjustment including the "optimization of csDMARDs dose or route of administration or intra-articular injections of GCs" is recommended. Thus, a new therapeutic agent can be embedded in a whole strategy with parallel optimization of the csDMARD and GC treatment. The idea of treating to target (T2T) for the treatment of RA patients has been around since the late 1990s. Many clinical studies (Ticora, BsSt, Camera) have demonstrated the superiority of a T2T approach. When I talk to physicians, I understand that most of them only rarely inject joints with GC. Therefore, I would like to create an issue on the T2T approach in reality including primary data, reviews, and real-life data demonstrating the general opinion and execution of T2T in treating RA.
This book is included in DOAB.
Why read this book? Have your say.
You must be logged in to comment.
Rights Information
Are you the author or publisher of this work? If so, you can claim it as yours by registering as an Unglue.it rights holder.Downloads
This work has been downloaded 147 times via unglue.it ebook links.
- 38 - pdf (CC BY) at Unglue.it.
- 105 - pdf (CC BY) at res.mdpi.com.
Keywords
- ACR response
- Adenosine
- ankylosing spondylitis
- anti-citrullinated protein autoantibodies
- anti-TNF
- baricitinib
- bioavailability
- biosimilar
- certolizumab pegol
- Computed Tomography
- csDMARDs
- cytokine
- DAS 28
- disease-modifying antirheumatic drugs
- DMARD
- effectiveness
- efficacy
- Fatigue
- foot
- Fracture
- fracture risk assessment tool
- Glucocorticoids
- golimumab
- Hand
- HAQ-DI
- herbal medicine
- IFN-γ, CD73
- IL-17A
- immunogenicity
- infliximab
- intra-articular injections
- Magnetic Resonance Imaging
- matrix metalloproteinase 3
- medication
- medicine
- methotrexate
- Methylation
- MTX
- n/a
- next-generation sequencing
- oral
- oral route
- osteoclast
- osteoporosis
- outcomes research
- Pain
- pain perception
- patient perspective
- Periodontal disease
- periodontitis
- personalized medicine
- Pharmacogenomics
- Porphyromonas gingivalis
- posology
- productivity
- pseudoerosions
- psoriatic arthritis
- Radiography
- recovery of function
- Régulation
- Rheumatoid arthritis
- rheumatoid factor
- Sleep
- Sleep Disorders
- Smoking
- subcutaneous route
- switching
- synovial fibroblasts
- Th1.17
- Therapy
- titration
- TNFα
- tofacitinib
- tolerability
- treat-to-target
- Tumor Necrosis Factor-Alpha Inhibitors
- Ultrasonography
Links
DOI: 10.3390/books978-3-03943-091-8Editions